These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34252268)

  • 1. Insight into the Therapeutic Potential of a Bicyclic Hydroxypyridone Compound 2-[(2,4-Dichlorophenyl)methyl]-7-hydroxy-1,2,3,4-tetrahydro-8H-pyrido[1,2-a]pyrazin-8-one as COMT Inhibitor in the Treatment of Parkinson's Disease: A Molecular Dynamic Simulation Approach.
    Subair TI; Akawa OB; Soremekun OS; Olotu FA; Soliman MES
    Chem Biodivers; 2021 Sep; 18(9):e2100204. PubMed ID: 34252268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
    de Beer AD; Legoabe LJ; Petzer A; Petzer JP
    Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospecting for new catechol-
    da Silva IR; Parise MR; Pereira M; da Silva RA
    J Biomol Struct Dyn; 2021 Oct; 39(16):5872-5891. PubMed ID: 32691671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
    Hitge R; Smit S; Petzer A; Petzer JP
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson's disease.
    Zou M; Wu Y; Lan Y; Xie H; Sun H; Liu W; Feng F; Jiang X
    Bioorg Chem; 2024 Jul; 148():107488. PubMed ID: 38797066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer's disease.
    Patel CN; Georrge JJ; Modi KM; Narechania MB; Patel DP; Gonzalez FJ; Pandya HA
    J Biomol Struct Dyn; 2018 Nov; 36(15):3938-3957. PubMed ID: 29281938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
    Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
    J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
    Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
    Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal Structure of Catechol O-Methyltransferase Complexed with Nitecapone.
    Iijima H; Takebe K; Suzuki M; Kobayashi H; Takamiya T; Saito H; Niwa N; Kuwada-Kusunose T
    Chem Pharm Bull (Tokyo); 2020; 68(5):447-451. PubMed ID: 32378542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
    Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
    Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.
    Pinheiro SD; Serrão MP; Silva T; Borges F; Soares-da-Silva P
    Eur J Pharmacol; 2019 Mar; 847():53-60. PubMed ID: 30685433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase.
    de Beer J; Petzer JP; Lourens ACU; Petzer A
    Mol Divers; 2021 May; 25(2):753-762. PubMed ID: 32108308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cheminformatics and virtual screening studies of COMT inhibitors as potential Parkinson's disease therapeutics.
    Moschovou K; Melagraki G; Mavromoustakos T; Zacharia LC; Afantitis A
    Expert Opin Drug Discov; 2020 Jan; 15(1):53-62. PubMed ID: 31744341
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility.
    Byers S; Buchler IP; DePasquale M; Rowley HL; Kulkarni RS; Pinder L; Kolobova A; Li C; Au V; Akuma D; Zhang G; Wei H; Cheetham SC; Barrow JC; Carr GV
    Psychopharmacology (Berl); 2020 Sep; 237(9):2695-2707. PubMed ID: 32474681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.
    Palma PN; Bonifácio MJ; Loureiro AI; Wright LC; Learmonth DA; Soares-da-Silva P
    Drug Metab Dispos; 2003 Mar; 31(3):250-8. PubMed ID: 12584150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.
    Espinoza S; Manago F; Leo D; Sotnikova TD; Gainetdinov RR
    CNS Neurol Disord Drug Targets; 2012 May; 11(3):251-63. PubMed ID: 22483291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and Computational Analyses of the Unique Interactions of Opicapone in the Binding Pocket of Catechol
    Takebe K; Suzuki M; Kuwada-Kusunose T; Shirai S; Fukuzawa K; Takamiya T; Uzawa N; Iijima H
    J Chem Inf Model; 2023 Jul; 63(14):4468-4476. PubMed ID: 37436881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.